Citeline and Norstella have completed a merger, first announced in June, to create one of the largest players in the pharmaceutical intelligence category.
Disc Medicine has charted a route to market for bitopertin, its drug candidate for rare disease erythropoietic protoporphyria (EPP), after meeting with the FDA.